January 02, 2026

Miami Cancer Institute Precision Oncology Symposium, Fourth Annual

This one-and-a-half-day symposium has been designed to provide an overview and opportunity to learn about the most recent advances in the treatment of solid tumors, including lung cancer, breast cancer, gastrointestinal tumors, genitourinary tumors, head and neck tumors, melanoma, sarcomas and brain tumors by novel targeted agents and treatment combinations.

Baptist Health South Florida

February 17, 2023

Study Finds Neoadjuvant Nivolumab Led to Improved 5-Year Survival Outcomes in Patients With Resectable NSCLC

The results from a 5-year follow-up analysis of a small clinical trial of patients with stage I to IIIA non­–small cell lung cancer (NSCLC) who were treated with nivolumab for 4 weeks before surgery s...

The ASCO Post

February 08, 2023

Uptake of Immune Checkpoint Inhibitors and Survival Among Younger and Older Patients With Advanced NSCLC

In a U.S. cohort study reported in JAMA Oncology, Voruganti et al found that the uptake of immune checkpoint inhibitor therapy for patients with advanced non–small cell lung cancer (NSCLC) has been as...

The ASCO Post

August 09, 2023

Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial

As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit wit...

The ASCO Post

September 21, 2023

NeoCOAST: Durvalumab Monotherapy vs Combined With Other Immunotherapies for Early-Stage NSCLC

An anti–PD-L1 monoclonal antibody in combination with other immuno-oncology agents may outperform treatment with the agent on its own in the neoadjuvant setting for patients with early-stage non–small...

The ASCO Post

January 13, 2025

Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality

Recent statistics showing reductions in lung cancer–related mortality may not address trends linked to tobacco use, air pollution, and asbestos exposure.

The ASCO Post

November 24, 2024

TROPION-Lung01 Update: Dato-DXd Shows Activity in Previously Treated Advanced Nonsquamous NSCLC

The novel trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) vs docetaxel conferred a numerical improvement in overall survival in previously...

The ASCO Post

April 21, 2025

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

In a recent article, the use of tyrosine kinase inhibitors in treating EGFR-variant lung adenocarcinoma is explored, drawing comparisons to their use in chronic myeloid leukemia, highlighting similarities and differences.

The ASCO Post

August 21, 2024

AI May Help Uncover Relationship Between Radiation Therapy for NSCLC and Cardiac Arrhythmia

“We are hoping to inform not only oncologists and cardiologists, but also patients receiving radiation treatment, about the risks to the heart when treating lung cancer tumors with radiation,” said st...

The ASCO Post